San Francisco, California
Calcilytix Therapeutics, a subsidiary of BridgeBio Pharma, is developing CLTX-305 (encaleret), a negative allosteric modulator of the calcium-sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (a genetic cause of hypoparathyroidism due to gain-of-function mutations in CaSR) and acquired hypoparathyroidism (usually secondary to prior neck surgery). The program is currently in Phase 2 for both indications.
BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine required to rapidly create lifesaving medicines for patients with unmet needs. Founded in 2015 by a team of industry veterans, the company has built a portfolio of 20 transformative drugs ranging from pre-clinical to late-stage development in multiple therapeutic areas including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. The company’s focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. We have offices in San Francisco, Palo Alto, Boston, New York, and Raleigh, with small satellites in other parts of the country.
To learn more, visit us at
Who You Are:
Calcilytix seeks an experienced, hands-on process chemist to join our rapidly expanding team in the role of Senior Director, Head CMC. This position is directed toward manufacturing and commercializing an existing small molecule drug candidate and reports to Calilytix’s Chief Scientific Officer.
Education, Experience & Skills Requirements:
What We Offer:
We will not accept unsolicited resumes from agencies. Please do not send agency resumes to our website or BridgeBio and affiliating employees.